{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"321"},{"groupId":"OG001","value":"137"},{"groupId":"OG002","value":"35"}],"units":"Participants"}],"description":"A Complete Hematologic Response (CHR) is obtained when all the following criteria are met: WBC ≤ institutional ULN; platelets ≤ 450,000/mm3; ≤20% basophils in peripheral blood; no blasts or promyelocytes in PB cells; \\< 5% myelocytes plus metamyelocytes in PB cells; no extra-medullary involvement including no hepatomegaly or splenomegaly.","groups":[{"description":"Adult participants PH+ CML-CP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).","id":"OG000","title":"CML-CP With Prior Imatinib Only"},{"description":"Adult participants Ph+ CML-AP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).","id":"OG001","title":"CML-AP With Prior Imatinib Only"},{"description":"Adult participants Ph+ CML-CP in addition to prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).","id":"OG002","title":"CML-CP"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): All participants who received at least one dose of study medication","reportingStatus":"POSTED","timeFrame":"Up to End of the Treatment (Approximately 7.5 years)","title":"Number of Participants With Complete Hematologic Response (Phase II)","type":"SECONDARY","unitOfMeasure":"participants"}